Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Imlygic Market Size And Revenue Forecast Through 2030
The expansion observed during the historic period was driven by a scarcity of treatment alternatives for unresectable melanoma, initial advances in immunotherapy, an increasing prevalence of melanoma cases, clinical confirmation of viral oncology approaches, and the integration of these therapies into oncology centers.
The forecast period’s growth is driven by the broadening of cancer immunotherapy pipelines, a rise in combination oncology studies, heightened funding for viral therapeutics, an uptick in melanoma diagnoses, and progress in genetic modification techniques. Key developments within this period involve the expansion of oncolytic virus treatments, a growing emphasis on immuno-oncology, the proliferation of injectable cancer treatments, a focus on targeting tumor sites locally, and a greater adoption of combination therapy methods.
Download A Free Sample Report For Comprehensive Market Insights:
#Imlygic Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing frequency of melanoma diagnoses is set to drive expansion in the imlygic market in the coming period. This form of skin cancer originates within melanocytes, which are the cells tasked with producing skin pigment. Factors like extended sun exposure, the use of tanning beds, and hereditary susceptibility are contributing to a rise in melanoma cases. Imlygic, also known as talimogene laherparepvec, functions as an oncolytic viral treatment administered via injection directly into melanoma tumors, aiming to induce localized tumor destruction and trigger a systemic immune response against the cancer. As an example, data from the National Library of Medicine in December 2023, a biomedical library based in the United States, revealed that the EU-27—comprising 27 European Union member nations—recorded 101,510 melanoma cases in 2022, with projections indicating an increase to 115,540 by 2040. Consequently, the escalating incidence of melanoma is fueling growth within the imlygic market.
The worldwide enhancement of healthcare infrastructure is anticipated to boost the imlygic market moving ahead. Healthcare infrastructure encompasses the physical assets, organizational frameworks, facilities, resources, and systems required to provide medical services to communities. Factors such as an aging worldwide population, a higher prevalence of chronic conditions, and ongoing technological progress are prompting this global infrastructure expansion. The success of imlygic depends on well-developed healthcare systems that can manage its specific requirements for storage, delivery, and coordinated administration as an oncolytic therapy. For instance, statistics from Cross River Therapy in September 2024, a U.S.-based provider of ABA therapy services, show that the American pharmaceutical industry generated $550 billion in revenue, with citizens spending $576.9 billion on medications in 2021, and projected outlays are expected to climb to between $605 and $635 billion by 2025. Hence, the global expansion of healthcare infrastructure is propelling growth in the imlygic market.
A surge in funding allocated to cancer research and development is forecasted to propel the imlygic market forward in the future. This type of financing provides monetary support for initiatives aimed at improving cancer treatment, prevention, and scientific investigation. The growing worldwide burden of cancer, a push for novel therapeutic approaches, and breakthroughs in precision medicine are all fueling increased investment in cancer research and development. Such heightened funding accelerates innovation, supports clinical trials, and boosts awareness, thereby fostering advancements and wider uptake of treatments like imlygic. For example, in July 2025, the National Cancer Institute, a U.S. government agency, reported that its available funding for fiscal year 2023 stood at $7.2 billion, which included $216 million from the Cures Act—representing a 5.7% increase, or $387.5 million more compared to the previous year. As a result, the growing investment in cancer research and development is stimulating expansion in the imlygic market.
Imlygic Market Segment Analysis Highlighting Growth Areas
The imlygic market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
3) By Application: Melanoma Treatment, Combination Therapy, Other Cancer Types
Imlygic Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the imlygic market are Amgen Inc.
Access The Complete Imlygic Market Report:
Imlygic Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the imlygic market in 2025. The regions covered in the imlygic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model